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Lung cancer has a high mortality rate and is often diagnosed at the metastatic stage. Recently, gefitinib, a molecule target
therapeutic drug, has offered a new approach for patients with non-small-cell lung cancer (NSCLC). This report describes
the effects of gefitinib on bone metastases in two patients with NSCLC. The pain induced by a bone metastasis was relieved
after the administration of gefitinib. Furthermore, the radiographs and CT findings showed sclerotic changes that matched
those of the metastatic bone tumor after gefitinib administration in both patients. It is believed that gefitinib inhibited
tumor cell proliferation and induced normal bone formation. In patients with NSCLC, gefitinib may be effective in the treat-
ment of bone metastases.
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Introduction
The prognosis of lung cancer patients with bone metas-
tases is very poor due to the lack of an effective treatment.
Recently, “gefitinib” (Iressa; AstraZeneca, Wilmington,
DE, USA), a new therapeutic drug for non-small-cell lung
cancer, has become available for clinical use. Inhibitors of
epidermal growth factor receptor (EGFR) tyrosine-kinase
are a new therapeutic option for non-small-cell-lung cancer
(NSCLC) patients in-locally advanced or metastatic stages
after being treated with platinum-based chemotherapy
1,2.
This paper presents two cases showing the remarkable
effectiveness of gefitinib on bone metastases of a lung ade-
nocarcinoma. The potential therapeutic effects of gefitinib
on bone metastases are discussed with a review of the rele-
vant literature
Case Reports
Case 1
A 52-year-old man presented with gradually increasing
pain in his neck and left upper arm over a 3 month period.
When he had visited our hospital, he could not move his
neck as a result of the pain. The plain radiographs demon-
strated a collapsed vertebral body at C-6 (Fig. 1A). The CT
scan findings of the lung revealed a solitary round tumor
with an irregular margin in the left upper lobe. The size was
2 cm in diameter. Technetium-99 bone scintigraphy demon-
strated multiple spinal bone metastases, which were diag-
nosed as a stage IV (T1N0M1). 
The patient underwent posterior decompression and
spinal fusion as palliative surgery. The visual analog scale
(VAS) improved to 2 cm from 10 cm. The pathological
diagnosis was adenocarcinoma. Although platinum-based
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did not improve. The patient rejected additional therapy.
Four months after the first operation, the C3-6 vertebral
body collapsed and he could sit up  （Fig. 1B） . Therefore,
the patient underwent C2-7 anterior body fusion as pallia-
tive surgery again. After surgery, the neck pain was
reduced, and the VAS was improved to 4 cm from 10 cm.
However, two months after the second operation, he pre-
sented with intolerable neck pain. The performance status
deteriorated to 3. Since the radiograph showed the progress
of osteolysis (Fig. 1C) and the primary focus progressed,
the oral administration of gefitinib 250 mg/day was started
as a second-line chemotherapy with informed consent. After
administration for one month, the pain was reduced to allow
walking. The performance status improved to
2. The VAS
improved to 4 cm from 10 cm. At three months after admin-
istration, the cervical metastatic lesions showed remarkable
increasing bone formation (Fig. 1D). The CT scan findings
of the cervical vertebrae confirmed osteosclerosis matched
with the metastatic bone tumor lesion  （Fig. 2） . The patient
survived for a further two years after having a recognized
bone metastasis. The activity of daily living (ADL) contin-
ued during the term of gefitinib administration.
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Fig. 1. Case 1. Plain radiographs of the cervical spine (A) Prior to surgery; radiograph showed collapse of the vertebral body at C-6
(B) four months after the first operation; C3-6 vertebral body collapse advanced (C) two months after the second operation (before
gefitinib administration); radiograph showed the progress of osteolysis. (D) 3 months after gefitinib administration; cervical metasta-
tic osteolytic lesions show remarkablly increasing osteosclerosis.
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BCase 2
A 78-year-old woman presented with cough and weight
loss over a 3 month period. The plain radiographs and CT
scan findings revealed a tumor in the left upper lobe of the
lung. A pathological diagnosis by sputum suggested an ade-
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Fig. 2. CT scans showing osteosclerosis in the metastatic bone tumor area at C-5. (A) CT scans obtained immediately before gefi-
tinib administration. (B) CT scans demonstrating remarkable bone formation at 3-months after gefitinib administration.
A B
Fig. 3. Case 2 3 months after surgery and gefi-
tinib administration (A) bone formation in the
pathological fracture, (B) cervical metastatic
lesions show remarkably increasing osteoscle-
rosis by plain radiography (C) cervical
metastatic lesions show remarkably increasing
osteosclerosis by CT scan.
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Bnocarcinoma. In addition, to the brain metastases, there
were multiple bone metastases of the pelvis, spine and
femur. She was diagnosed with stage IV (T4N3M1) lung
cancer. The oral administration of gefitinib 250 mg/day was
commenced with informed consent. One week later, she
suffered from the pathological fracture of the femur, and
underwent internal fixation. Three months after surgery,
remarkable bone formation and union was observed in the
plain radiograph (Fig. 3A). She was able to walk without
pain. The cervical metastatic lesions revealed remarkable
bone formation in the plain radiographs and CT scan find-
ings (Fig. 3B and C). She was still alive one year after the
recognized bone metastasis with an improvement in the
pain and ADL after gefitinib administration.
Discussion
Lung cancer has a high mortality rate and is often diag-
nosed at the metastatic stage. Recently, gefitinib has offered
a new approach for patients with NSCLC. Response rates of
between 9~18% have been reported in phase II trials for
gefitinib in unselected patients with NSCLC. A never
smoking status, female gender and Asian ethnicity are asso-
ciated with an increased sensitivity to gefitinib
2.
In our cases, the patients with bone metastases of a lung
adenocarcinoma improved temporarily after palliative
surgery but deteriorated a short time later. According to the
prognostic score for a metastatic spinal tumor, both cases
had a predicted prognosis (mortality) of within six months,
and were indicated as palliative surgery, or supportive care
only
3,4. However, the administration of gefitinib allowed a
longer period of survival and improved pain and ADL. 
The plain radiographs and CT scan findings suggested
remarkable bone formation matched with the metastatic
osteolytic lesion. Normanno et al.
5,6 reported that gefitinib
inhibited the ability of human bone marrow stromal cells to
induce osteoclast differentiation by reducing the level of
RANKL expression. In the clinical cases, it is believed that
gefitinib restrains bone destruction by inhibiting osteoclast
differentiation in addition to the normal pharmacological
phenomenon, where it inhibits EGFR-TK of cancer cells
directly as well as the osteoclast activation factor (PTHrP)
from cancer cells  （Fig. 4） . In hindsight, it would have been
good to examine the bone growth in more detail (bone min-
eral density, bone turnover marker, and more). However,
the patients have since died. This will certainly be examined
in future patients.
To date, some studies reported that gefitinib reduces the
bone or brain metastasis of NSCLS
7. Their patients were
treated with gefitinib and combination with bisphosphonate,
radiation, etc
8. In the present two cases, gefitinib extended
their prognosis. In future, gefitinib should be considered
among all current treatment options for cases where there is
a surgical indication of bone metastases of lung cancer.
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Fig. 4. Gefitinib inhibits osteoclast differentiation in two ways. gefitinib inhibits osteoclast differentiation and restrains bone destruc-
tion by reducing the expression of RANKL, inhibiting EGFR-TK in cancer cells and inhibiting osteoclast activation factor (PTHrP)
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